Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis.

ABSTRACT:

Aim

The purpose of the current study was to determine if long term treatment with an endothelin-A (ETA) receptor antagonist attenuates the progression of coronary plaques in patients with coronary endothelial dysfunction.

Methods

Thirty-five patients with non-obstructive coronary disease and coronary endothelial dysfunction were randomized in a double blind manner to treatment with placebo or ETA receptor antagonist Atrasentan (10 mg) for six months. Endothelial function was assessed by the change in coronary blood flow and coronary artery diameter in response to intracoronary acetylcholine. Normalized mean total atheroma volume (TAVMEAN), percent atheroma volume (PAV) and changes of atheroma volume were assessed by intravascular ultrasound (IVUS) at baseline and 6-month fol

SUBMITTER: Yoon MH 

PROVIDER: S-EPMC3795901 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature